The HERO program has two parts: the HERO Registry and the HERO-HCQ Trial. The HERO Registry is asking hundreds of thousands of U.S. healthcare professionals to join, including nurses, therapists, physicians, emergency responders, food service workers, environmental services workers, interpreters, and transporters anyone who…
The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of NKTR-214 given in combination with KEYTRUDA or TECENTRIQ. We want to find out what effects, good or bad, the study drug has on the body and cancer when combined with KEYTRUDA or TECENTRIQ. The study will recruit participants at least 18…
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
The main purpose of this study is to learn more about the study drug called LY3321367. The study wants to know more about the following: The safety of LY3321367 alone and in combination with another drug called LY3300054 and any side effects you might have Whether LY3321367 is tolerable when taken alone and in combination with LY3300054. How much…
We are conducting a CoVPN-funded study to understand if monoclonal antibodies can protect people exposed to SARS-COV-2 from developing the COVID-19 disease that it causes. If you live with someone recently diagnosed with COVID, you may be eligible to participate in one or more study visits. At each visit you will be asked to provide blood, nasal, and urine…